Reading your histopathology report

'In Situ' vs — 'Invasive': What the Difference Means

If your histopathology report uses the words 'in situ' or 'invasive', you have found one of the most consequential sentences on the page. Most people are handed this document without anyone explaining what it means. This page does that.

Medically reviewed by Dr. Muralidhar Muddusetty, Surgical Oncologist, MBBS (AIIMS) · MS Surgery (AIIMS) · DNB Surg Onc · MRCS (Edinburgh) · Last reviewed September 2026

A critical line on the report — 'In situ' and 'invasive' describe what abnormal cells are doing — not just that they are there.
Not the same finding — The distinction changes what treatment is considered and how the situation is staged.
Written for another doctor — Histopathology reports use clinical shorthand. This page translates the most important terms into plain language.
Always discuss with your oncologist — This page explains terminology. Only your treating doctor can interpret your individual report.

Book Free Consultation 1800 202 8726

4.8 · 800+ Google reviews · 15,000+ patients treated

17+

Cancer Specialists
on Panel

96.9%

Breast Cancer
Survival Rate*

15,000+

Patients
Treated

4.8★

Google Rating
(800+ reviews)

The words 'in situ' and 'invasive' describe whether abnormal cells have stayed within their original layer of tissue or crossed into surrounding tissue. This is one of the most important findings on a histopathology report. Your oncologist will explain exactly what it means for your specific situation.

What is the difference between in situ and invasive?

Feature	In Situ	Invasive
What the cells do	Stay within the tissue layer where they began	Cross into surrounding tissue
Terms you may see on the report	CIS, DCIS, LCIS, LSIL, carcinoma in situ	Invasive carcinoma, infiltrating carcinoma
Ability to spread to lymph nodes or distant organs	Not seen in purely in situ disease	Possible — assessed as part of staging
What typically follows	Local treatment, close monitoring, or surgery depending on type and location	Staging to assess extent, then a treatment plan
How urgency is usually framed	Managed carefully, though not always an immediate emergency	Typically warrants prompt staging and treatment planning

Is in situ actually cancer?

Yes — and no. Cells described as in situ are abnormal and taken seriously, but pathologists and oncologists distinguish them from invasive carcinoma because they have not yet crossed into surrounding tissue.

The term comes from Latin: in situ means 'in place'. The abnormal cells are still contained within the layer of tissue where they started — the lining, the duct, or the surface — and have not broken through the boundary into the tissue below or around them.

Whether in situ disease needs treatment, and what kind, depends on its location, type, and extent. Your oncologist will discuss the options that apply to your specific result.

Terms on your report and what they mean

Carcinoma in situ (CIS): Abnormal cells confined to their original tissue layer. The specific organ and layer are always named alongside — for example, DCIS names the duct in the breast.
DCIS — Ductal Carcinoma in Situ: Abnormal cells inside the milk ducts of the breast that have not spread beyond the duct wall. A common finding on mammogram-detected biopsies.
LCIS — Lobular Carcinoma in Situ: Abnormal cells in the breast lobules. Often treated as a marker of increased risk rather than a cancer requiring immediate surgery — your oncologist will explain the distinction.
LSIL and HSIL: Low-grade and high-grade squamous intraepithelial lesions, most often found on cervical biopsies. Both are in situ changes. HSIL needs prompt follow-up.
Invasive carcinoma: Abnormal cells that have crossed out of their original tissue layer into surrounding tissue. Also called infiltrating carcinoma — the two words mean exactly the same thing.
Microinvasion: A very small focus of invasive cells found alongside in situ disease. Its significance varies by cancer type. Your oncologist will explain where it sits in your specific staging.
Infiltrating carcinoma: Exactly the same as invasive carcinoma. Some laboratories have used this term for decades; others prefer 'invasive'. They are not different diagnoses.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile

Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile

Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile

Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile

Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile

Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile

Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile

Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile

Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile

Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile

Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile

Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile

Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile

Interventional Radiologist

Dr. Mohammed Imran

View Profile

Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile

Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

Questions to ask your oncologist at the next appointment

What does in situ or invasive mean specifically for my cancer type and location?
If the report says in situ, is there any component of invasive disease as well?
What is the grade of the cells found, and what does that mean alongside this finding?
Does this result change the staging conversation?
What happens next — more imaging, further biopsy, or can treatment planning begin?
Are there terms on the report you can walk me through before we discuss next steps?

Does this distinction change the outlook?

Yes — it is one of the factors that shapes the treatment plan, the staging, and the overall picture your oncologist is building from your reports.

In situ disease, when it is purely in situ with no invasive component, is generally considered at an earlier point in the disease process than invasive disease. That does not mean it is always minor — some in situ findings need prompt treatment — but it does change what is being planned for.

Invasive disease means cells have crossed into surrounding tissue, which opens the question of whether staging needs to assess lymph nodes or other organs. That assessment drives the conversations about surgery, systemic treatment, and follow-up.

These are generalisations. The same word on two different reports can carry very different weight depending on the organ, the grade, and the full clinical picture. Your oncologist will make this specific to you.

Did you know?

The word 'infiltrating' appeared on pathology reports for decades before 'invasive' became standard. Both words mean exactly the same thing.

If your biopsy report says 'infiltrating carcinoma' and a later letter uses 'invasive carcinoma', they are describing the same finding — not two different problems.

Source: WHO Classification of Tumours, 5th Edition

Explore 114 more Waiting For and Understanding Your Report topics

Reading Your Histopathology Report

Cytology Reporting Systems

Gleason & Prostate Biopsy Reporting

Grade, Differentiation & Mitotic Index

Margins, LVI and PNI

Staging on a Biopsy Report

Waiting for Results

All Waiting For and Understanding Your Report →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726

Common questions

Frequently asked questions

Is in situ cancer?

In situ disease is genuinely abnormal — pathologists describe it as a pre-invasive finding, and it is taken seriously enough to require treatment or close surveillance in most cases. Whether it is called cancer in everyday language depends on the medical team and the specific type. What matters more than the label is what your oncologist recommends doing about it and why. Ask for that explanation clearly at your next appointment.

My report says 'infiltrating carcinoma' — is that the same as invasive?

'Infiltrating' and 'invasive' mean exactly the same thing in pathology. Some laboratories have used 'infiltrating' for decades; others prefer 'invasive'. If your biopsy report says 'infiltrating ductal carcinoma' and a later letter from your oncologist says 'invasive carcinoma', they are describing the same finding — not two different problems. If there is any doubt, ask your pathologist or oncologist to confirm.

Can in situ disease become invasive?

In situ disease is understood to represent a stage before invasion has occurred. Whether any individual case will progress to invasive disease, and how quickly, is not something a report can answer — it depends on the type, the grade, and factors specific to the individual. This is one reason in situ findings are treated seriously rather than simply observed. Your oncologist will explain the approach recommended for your type and what the goal of that approach is.

My report mentions 'microinvasion' — what does that mean?

Microinvasion means pathologists found a very small focus of cells that have crossed into surrounding tissue alongside a larger area of in situ disease. How significant that is depends on the organ, the size of the invasive focus, and the cancer type. It is not the same as fully invasive disease, but it is also not purely in situ. Your oncologist will explain where microinvasion places your result on the staging spectrum and what it means for treatment planning.

Does 'invasive' mean the cancer has spread to my other organs?

'Invasive' on a histopathology report means cells have crossed into surrounding tissue — not that cancer has spread to other organs or lymph nodes. Spread to distant organs is called metastasis, and it is a separate question answered through staging scans and lymph node assessment, not the biopsy report alone. If your report says invasive, the next conversation will likely be about which staging investigations are needed to answer that spread question.

Should I get a second opinion on my histopathology report?

A second pathology opinion is reasonable to ask for, particularly when the finding sits on the boundary between in situ and invasive, when the grade or subtype affects major treatment decisions, or when you are moving to a different centre for treatment. It does not imply distrust of the original laboratory — many oncologists request second opinions on complex cases themselves. Ask your treating oncologist whether a second opinion would change anything about your management plan. The answer will tell you whether it is worth pursuing in your situation.

Full index